ClinicalTrials.gg

Program

SCT650C

A development code.

Its studies are mostly in Hidradenitis Suppurativa · Axial Spondyloarthritis · Autoimmune Diseases, led by Sinocelltech Group.

Furthest: phase 2, since Dec 11, 20233 company-led studies, 3 open or runningNext primary completion: Mar 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinocelltech Group33 open or runningphase 2since Dec 11, 2023May 29, 2023Mar 12, 2027phase 2 · NCT07244510

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2023First study: phase 1 study in Autoimmune DiseasesFirst studyNCT05894707 · 32 planned · Australia
  2. Dec 11, 2023Phase 2 study in Axial SpondyloarthritisNCT06197009 · 168 planned · Turkey
  3. Nov 17, 2025Phase 2 study in Hidradenitis SuppurativaNCT07244510 · 60 planned · Turkey (Türkiye)

Ahead

  1. Mar 12, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07244510

TargetBeta

IL17A →read by rule
“SCT650C is a novel humanized monoclonal antibody against human IL-17A developed by Sinocelltech which is now on the first step of clinical evaluation.”study text, by rule · the study

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
secukinumabruleNovartisphase 4128
ixekizumabruleEli Lillyphase 438
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
tibulizumabruleEli Lillyphase 25
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07244510Hidradenitis Suppurativa · Turkey (Türkiye)2RecruitingMar 12, 202760
NCT06197009Axial Spondyloarthritis · Turkey2Not yet recruitingJul 1, 2026168
NCT05894707Autoimmune Diseases · Australia1Not yet recruitingNov 202332

How it is read

Names in the registry

  • “SCT650C”, 3 entries

Codes read as this program: SCT650C.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.